tickerreport.com
Neutralwww.tickerreport.com ·
Liminatus Pharma Nasdaqlimn Issues Quarterly Earnings Results
TradeWorldlanguages PalmaCancerDiseases
Topic context
This topic has been covered 247737 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedNo concrete commercial mechanism. The article reports a small-cap pre-clinical biotech's quarterly loss and stock price movement. No product revenue, supply chain, or regulatory catalyst. Impact is limited to the single company's equity; no sector-wide or commodity effect.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Liminatus Pharma reported quarterly earnings loss of $0.03 per share.
- Stock traded down 2.2% to $0.18 with volume of 754,434 shares.
- Market cap is $8.08 million, P/E ratio -1.20.
- Weiss Ratings reaffirmed 'sell (e+)' rating.
- Company is a pre-clinical-stage immuno-oncology firm founded Nov 1, 2020.
Related stories
finance.yahoo.com
Ncmi Q1 2026 Earnings Transcript
finance.yahoo.com
Transcript Valneva Q1 2026 Earnings
zerohedge.com
Europe Primed Lower Open Amid Lack Progress Usiran Hefty Speaker Slate Nvidia Earnings Due
finance.yahoo.com
Aytu Aytu Q3 2026 Earnings
timesofindia.indiatimes.com